Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evogene Ltd (EVGN) Fair Value & Analysis

Healthcare · US · Market cap $6.4M

Price$0.4990
Fair Value$1.11
Upside+122.4%
Quality80/100
Evidence: Low Range $0.8400 – $1.39

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Evogene Ltd (EVGN) currently trades at $0.4990, while our model-based Fair Value estimate is $1.11 — implying the stock looks roughly 122.4% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Evogene Ltd (EVGN) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $1.11 versus a price of $0.4990 — about +122% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EVGN?
Our 21-model fair value for Evogene Ltd is $1.11 (as of Jun 23, 2026), built from audited fundamentals. The current price is $0.4990.
What is the quality score of EVGN?
Evogene Ltd has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.